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Summary The antiepileptic efficacy and tolerability of oxcarbazepine, used both as
monotherapy and adjunctive therapy, were observed for 1 year in 202 adult patients,
aged 17—83 years, with newly diagnosed or refractory partial epilepsy in clinical
practice in Italy. At first observation, the seizure free rate was 72.2% in newly
diagnosed patients given monotherapy, 40% in patients in whom oxcarbazepine
replaced another monotherapy and 10.3% in patients given oxcarbazepine as adjunc-
tive therapy. At least 50% reduction in seizure frequency was achieved in 90.7, 72 and
57%, respectively. Efficacy increased with the duration of treatment ( p < 0.0001). In
the 160 completers the seizure free rate was 61.3% with monotherapy and 28% with
adjunctive therapy. 16.3% of patients reported adverse effects, mainly sedation and
sleepiness; 5% discontinued oxcarbazepine because of adverse events. OXC is an
effective and well-tolerated antiepileptic agent for the long-term treatment of
partial epilepsy in adults.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Oxcarbazepine (OXC) is a new antiepileptic drug
(AED) approved for the treatment of both simple
and complex partial seizures with or without sec-
ondary generalization, either alone or in combina-
tion, in newly diagnosed patients and in non-* Correspondence to: Department of Neurology, DPMSC, Ospe-
dale S. Maria della Misericordia, Padiglione Specialita`, IV piano,
Piazzale S. Maria della Misericordia, 33100 Udine, Italy.
Tel.: +39 0432 552720; fax: +39 0432 552719.
E-mail address: giada.pauletto@libero.it (G. Pauletto).
1059-1311/$ — see front matter # 2006 British Epilepsy Association
doi:10.1016/j.seizure.2005.12.008responders to alternative agents. It was developed
through structural changes to carbamazepine (CBZ)
with the intention of achieving a more favourable
pharmacokinetic profile associated with fewer
undesirable effects. It has proved to be a distinctly
different drug to CBZ, characterized by minimal
cytochrome P-450 metabolization, calcium channel
modulation in addition to sodium current blockade
and better tolerability. It has also proved to be
effective as add-on or replacement treatment in
patients in whom CBZ has not achieved sufficient
seizure control.1. Published by Elsevier Ltd. All rights reserved.
Oxcarbazepine reduces seizure frequency in a high proportion of patients 151
a Tolep1.The compound has been extensively evaluated
within the context of randomised, controlled, dou-
ble blind clinical trials both as monotherapy and as
adjunct therapy.2,3 OXCmonotherapy has been com-
pared to monotherapy with the main traditional
AEDs, including valproate, phenytoin, and CBZ in
newly diagnosed patients. Antiepileptic efficacy
was similar, the overall seizure-free rate with OXC
being 60%.4—12
Double-blind studies in surgery candidates with
refractory epilepsy have shown that rapid OXC titra-
tion (2400 mg in one day) is well tolerated and that
one-third of patients become seizure-free after two
days of treatment.13,14
However, experience has shown that compounds
that yield very promising results in ‘‘gold standard’’
clinical trials may be of little use in clinical practice
on account of unforeseen developments in the
uncontrolled conditions of clinical practice, where
patients do not meet the rigid eligibility criteria of a
clinical trial and usage is not monitored according to
a rigorous experimental plan.15,16
Moreover, little is known about the natural his-
tory of epilepsy. Remissions may occur sponta-
neously, independently of therapy. This
phenomenon, which is very difficult to quantify,
needs to be taken into account for the evaluation
of long-term efficacy.
Observational post-marketing surveillance stu-
dies performed in the setting of clinical practice
have been devised to overcome the shortcomings of
clinical trials.
The purpose of this study was to record the
antiepileptic efficacy and tolerability of OXC, used
both as monotherapy and adjunctive therapy, in a
population of adult patients with newly diagnosed or
refractory partial epilepsy in clinical practice in
Triveneto (North of Italy).
Materials and methods
This was a prospective, multicenter, observational
trial involving 18 centres in Triveneto (Italy), which
are members of the Triveneto Epilepsy Study Group.
Co-operative patients with a clinical diagnosis
of partial epilepsy attending the out-patient
clinics of the centres were included, provided that
they were at least 17 years old and were not
affected by haematological diseases and/or con-
ditions associated with electrolyte imbalance
(serum Na+ <130 mEq/l at baseline). Also preg-
nancy, lactation, major psychiatric diseases, a
history of abuse and a history of hypersensitivity
to CBZ or other components of OXC tablets were
exclusion criteria.Demographic information and a detailed medi-
cal history related to epilepsy were collected,
specifying its category according to the Interna-
tional League against Epilepsy (ILAE) classification
and whether it was symptomatic, idiopathic or
cryptogenic in order to make the clinical definition
of the various diagnoses more homogeneous; age at
onset of epilepsy and seizure frequency in the last
3 months were also noted. Any available neuroi-
mages were evaluated. Information on OXC treat-
ment included date of introduction, dosage
regimen, duration of treatment, usage as mono-
therapy or as adjunctive therapy; in the event of
use as adjunctive therapy, the additional AEDs
used. Investigators titrated the drug according to
their standard clinical practice, using uncoated
300 mg tablets.a
Physical examination findings and the results of
routine laboratory tests (CBC + differential, elec-
trolytes, serum creatinine, blood urea nitrogen,
transaminases, GGT) and of EEG were collected.
Upon completion of this first phase of study, the
patients were asked whether they were willing to
enter the second phase of the study, a 1-year
observation period. If they were, they were given
a diary to fill in, where they wrote down the
number and type of seizures, any contributing
factors, such as lack of sleep, alcohol intake,
menses, etc., dosage of OXC and other AEDs,
undesirable effects and changes in concomitant
treatment. During the 1-year observation period
they attended the centre for a physical examina-
tion and blood sampling for routine laboratory
tests every 3 months.
The therapeutic response was evaluated using a
6-item semi-quantitative rating scale expressing the
reduction in seizure frequency: <50%, 50%, 75%,
seizure-free (SF), no change, worse.
The evaluation of tolerability was based on eli-
cited adverse events (AE) during visits, neurological
examination findings and routine laboratory tests.
AE were considered to be severe when they required
medical intervention and/or caused reduction in
OXC dosage and/or its discontinuation.
Efficacy data were analysed using the test of
Wilcoxon—Mann—Whitney and the test of Jonch-
eree-Terpestra, according to duration of treat-
ment and the type of seizures and/or epileptic
syndrome.
Patients who no longer met the eligibility cri-
teria during the trial (e.g. appearance of general-
ized epilepsy not diagnosed previously) were
considered violators and excluded from the statis-
tical analysis.
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Table 2 Antiepileptic treatment
OXC usage (% patients)
Monotherapy 129 (69%)
Newly diagnosed 54 (28.9%)
Refractory to other AED/ 75 (40.1%)
Other AED not tolerated
Adjunctive therapy 58 (31%)
Mean number of combined
AEDs, range
2.7 (2—5)Results
Patient population
The study population consisted of 202 patients,
including equal proportions of both sexes and cover-
ing all age groups, from teenagers to the very old
(range: 17—83 years). The patient population also
covered a very broad range of durations of disease
(from 1 to 67 years) and of seizure frequencies (from
0 to 90 seizures per month). Most patients were
suffering from symptomatic or cryptogenic epilepsy
(47% and 49%, respectively); more than half of the
patients had complex partial seizures (52%) and/or
secondarily generalized partial seizures (53%). Ele-
ven patients were suffering from generalized tonic-
clonic seizures and were removed from the analysis
(Table 1).
Another four patients discontinued OXC treat-
ment because of inefficacy, so the efficacy popula-
tion amounted to 187 patients.
A total of 25 patients (12.5%) discontinued OXC
treatment during the first phase of the study. The
main reason for discontinuing treatment was unde-
sirable effects (n = 10—5%),mainly involving the cen-
tral nervous system (dizziness, ataxia, headache).
Other reasons were poor compliance (n = 6), ineffi-Table 1 Main characteristics of the patient popula-
tion
Characteristic N = 202
Sex, n (%)
Males 96 (47.5)
Females 106 (52.5)
Age (years)
Mean  S.D. 47.5  16.7
Range 17—83
Duration of epilepsy (years)
Mean  S.D. 16.0  15.9
Range 1—67
Mean monthly seizure frequency
in the last 3 months before
introduction of OXC, range
8.5 (0—90)
Etiology, n (%)
Idiopathic 8 (4)
Symptomatic 95 (47)
Cryptogenic 99 (49)
Type of seizure, n (%)
Partial seizures 191 (94.5)
Simple 29 (14.4)
Complex 105 (52)
Secondary generalization 107 (53)
Generalized tonic-clonic seizures 11 (5.5)cacy (n = 5), undesirable effects and inefficacy
(n = 4).
Another 17 patients (12.5%) discontinued OXC
treatment during follow-up, mainly because of per-
sonal reasons or clinical decisions independent of
tolerability: inefficacy (3.1%), persistence of unde-
sirable effects (1.9%), poor compliance (1.9%), lost
to follow-up (5.6%).
Thus, 160 patients completed the 1-year follow-
up period.
Treatment
Two-thirds of the patients included in the efficacy
population were given OXC alone; more than half of
these patients had not responded to or had notMost commonly combined AEDs (n patients %)
Phenobarbital 45.3%
Valproate 25.0%
Lamotrigine 23.4%
Levetiracetam 14.7%
Topiramate 12.5%
Clonazepam 10.9%
Phenytoin 10.9%
Carbamazepine 9.4%
Clobazam 6.2%
Gabapentin, Vigabatrin, Diazepam,
Barbesaclone, each
1.6%
OXC dosage (mg)
Mean–—all patients 1174
Mean–—monotherapy 1049
Mean–—adjunctive therapy 1405
Range 300—3000
N–—Percentage of patients given
<1000 mg 87—43.1%
1000—1500 mg 79—39.1%
>1500 mg 36—17.8%
b.i.d. regimen 76.5%
t.i.d. regimen 23.5%
Duration of treatment
(days)–—mean  S.D.
307  212
Percentage of patients treated for
<6 months 58 (28.8%)
6—12 months 74 (36.6%)
>12 months 70 (34.6%)
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Figure 2 Effect of duration of therapy on the reduction
in seizure rate achieved with OXC monotherapy.tolerated another AED. The remaining third were
given combinations of 2—5 AEDs. The AED that was
most commonly combined with OXC was phenobar-
bital (45.3% of patients); nevertheless, modern AEDs
were given to more than half of the patients (53.8%)
(Table 2).
The dosage of OXC varied considerably from 300
to 3000 mg daily, being on average slightly higher
when OXC was given as adjunctive therapy (1400 mg
versus 1050 mg daily). Most of the patients were
given low dosages below 1000 mg daily (43.1%), but
the proportion of patient given high dosages above
1500 mg daily was not negligible (17.8%) (Table 2).
Mean duration of treatment was 10 months.
Efficacy
Success rates in terms of reduction in monthly
seizure frequency were highest in the subgroup of
newly diagnosed patients given OXC monotherapy:
nearly three patients out of four became seizure
free. Fairly high success rates were achieved also in
the subgroup of patients given OXC to replace
another AED monotherapy (reduction in seizures
by 50% in 72% and complete elimination of seizures
in 40%) (Fig. 1). Even in patients given OXC as
adjunctive therapy results were not negligible, as
a reduction in seizure frequency by more than 50%
was achieved in more than half the patients (56.9%);
a reduction by more than 75% was achieved in just
over one-third (34.5%) and 10.3% of patients became
seizure-free.
Efficacy was greater when treatment had been
continued for more than 6 months not only when
OXC was given as monotherapy, but also when it
was given as adjunct therapy (Figs. 2 and 3).
The difference between success rates in patientsFigure 1 Reduction in seizure rate achieved by OXC
monotherapy in newly diagnosed patients (n = 54) and
following replacement of other AED (n = 75).treated for less than 6 months and those treated
for 6 months or more was statistically significant
( p < 0.0001). No significant difference in efficacy
was found according to type of seizure or epileptic
syndrome.
The success rates achieved during the first phase
actually improved during the second phase, espe-
cially in the group of patients in whom OXC was used
as adjunctive therapy (Fig. 4). Overall, 34 patients
improved versus phase 1; out of these eight patients
on adjunctive OXC therapy improved without any
changes in concomitant AEDs. Moreover, OXC dosage
was increased only in two patients by 300 mg daily.
Tolerability
A total of 33 patients (16.3%) reported undesirable
effects in the first phase. Most of them involved the
central nervous system: sedation (n = 12—5.9%),Figure 3 Effect of duration of therapy on the reduction
in seizure rate achieved with combination therapy OXC + -
other AED.
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Figure 4 Reduction in seizure rate achieved by OXC
monotherapy and OXC combination therapy after 1 year
of observation.sleepiness (n = 7—3.5%), dizziness (n = 5—2.5%) and
ataxia (n = 4—2%). Other infrequent undesirable
effects were: hyponatremia (n = 3—1.5%); asthenia,
headache and nausea, skin rash (all n = 2—1%);
vomiting, constipation, increase in transaminases
(all n = 1—0.5%).
During follow-up mild or moderate undesirable
effects were reported in 9% of patients. They were
similar to those reported in the first phase.
Discussion
This study shows that OXC is effective and well
tolerated in the treatment of partial seizures in
clinical practice, independently of the type of sei-
zure and the mode of use, i.e. as monotherapy or
adjunctive therapy. In particular, it shows that OXC
monotherapy is able to improve seizure control in
patients who do not respond adequately or do not
tolerate other AEDs and that OXC adjunctive ther-
apy improves seizure control in combination with
other AEDs. It also shows that therapeutic benefits
are not only maintained in the long-term, but actu-
ally increase with time, especially after the first 6
months of treatment.
The benefits were achieved with a medium to low
mean dosage (about 1200 mg daily).
The results of this study are better than those
observed in retrospective studies: Friis et al.17
reported a 32—48% improvement in seizure control
with OXC in a large multicenter trial in 947 patients
with various types of seizures, covering 9 years of
experience. Van Parys and Meinardi18 assessed the
outcome of 260 epileptic patients who replaced CBZ
with OXC and followed them up for 43 months: only
8% were seizure free and 32% experienced at least a50% reduction in seizure frequency. Seizure control
was adequate in 41.7% of children with refractory
epilepsy treated with OXC for 5 years.19
On the other hand, the results of this study are
consistent with those of other recent, prospective
open-label studies. Sturm et al.20 reported a sei-
zure free rate of 70% in 362 newly diagnosed
patients on monotherapy for 1 year versus 72.2%
in this study. Walker et al.21 reported a similar
success rate in refractory patients with OXC com-
bination therapy in terms of seizure frequency
reduction (50% versus 57%), whereas the proportion
of seizure free patients was slightly lower (4.8%
versus 10.3%). Zeising et al.22 reported an overall
seizure free rate of 58.8%, results being better in
subjects onOXCmonotherapy aswas the case in this
study (66.8% versus 61% with monotherapy and
39.8% versus 28% with adjunctive therapy). Also
in this study the maintenance dose was about
1000 mg daily.
Long-term open-label extensions of controlled
trials show that therapeutic benefits are maintained
in the long-term, as in this study: 48.2% of patients
improved significantly and 7% became seizure free in
a population of patients with refractory epilepsy in a
study by Minecan et al.23. Long-term efficacy is
supported also by the studies by Beydoun et al.24
and Gilliam et al.25, who documented continuation
of OXC therapy for 4 years in 75—90% of patients
with refractory epilepsy, indicating that the drug
was well tolerated and provided adequate seizure
control.
Undesirable effects were few and well known
adverse reactions to the drug.26
In conclusion, this observational trial has shown
that OXC is an effective and well-tolerated antie-
pileptic agent when it is used in clinical practice for
the long-term treatment of partial epilepsy in adults
both as monotherapy and adjunctive therapy.Acknowledgments
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